Phase II trial of oral doxifluridine plus oral levo-leucovorin in unresectable hepatocellular carcinoma

M. Colleoni, M. Di Bartolomeo, E. Bajetta, F. Nole, P. Nelli, C. Carnaghi, G. Vicario, M. Del Vecchio, A. Bono

Research output: Contribution to journalArticle

Abstract

Systemic chemotherapy with currently available agents in unresectable HCC has a minimal impact on disease progression and a predictable response rate of 2, day 1 through 5, cycles being repeated every 10 days. Thirty-seven patients with unresectable HCC entered the study and are evaluable for response and toxicity. Three partial responses have been observed, to a global response rate of 8% (95% confidence interval 2-22%). After a median observation time of 12 months, the median survival was 7 months, with a median time to progression of 4 months. Main toxicity was diarrhea; severe in 30% of the patients. One patient died as a result of uncontrollable diarrhea. In view of the limited activity observed, further trials with this schedule are not warranted.

Original languageEnglish
Pages (from-to)603-606
Number of pages4
JournalOncology Reports
Volume2
Issue number4
Publication statusPublished - 1995

    Fingerprint

Keywords

  • Doxifluridine
  • Hepatocellular carcinoma
  • Leucovorin
  • Oral chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this